Multiple, repeated filgrastim treatment cycles to recover severe, recurring pegylated interferon-related neutropenia.
Manfredi
Roberto
R
Sabbatani
Sergio
S
D000328:Adult; D000998:Antiviral Agents / Q000627:therapeutic use; D000069585:Filgrastim; D005838:Genotype; D016179:Granulocyte Colony-Stimulating Factor / Q000008:administration & dosage / Q000627:therapeutic use*; D016174:Hepacivirus / Q000235:genetics / Q000378:metabolism; D006526:Hepatitis C / Q000188:drug therapy; D006801:Humans; D000077190:Interferon alpha-2; D016898:Interferon-alpha / Q000009:adverse effects*; D008297:Male; D009503:Neutropenia / Q000139:chemically induced* / Q000188:drug therapy*; D011092:Polyethylene Glycols / Q000009:adverse effects*; D011994:Recombinant Proteins; D012008:Recurrence; D012254:Ribavirin / Q000627:therapeutic use; D016896:Treatment Outcome
D000998:Antiviral Agents; D000077190:Interferon alpha-2; D016898:Interferon-alpha; D011994:Recombinant Proteins; D016179:Granulocyte Colony-Stimulating Factor; D011092:Polyethylene Glycols; D012254:Ribavirin; D000069585:Filgrastim; C100416:peginterferon alfa-2a